Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BTK SH2 domain inhibitor
- Development stage
- Preclinical
- Lead developer
- Recludix Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BTK SH2 domain inhibitor is a preclinical-stage small molecule program being developed by Recludix Pharma for the treatment of autoimmune and inflammatory diseases, including multiple sclerosis (MS) and chronic spontaneous urticaria (CSU). Unlike traditional Bruton's tyrosine kinase (BTK) inhibitors that target the kinase domain, this first-in-class therapeutic approach targets the SH2 domain of BTK. By inhibiting the SH2 domain, the drug disrupts the formation of the pro-inflammatory signaling complex and blocks the scaffolding function of BTK. This mechanism offers exquisite selectivity over other kinases (such as TEC) and the broader SH2ome, potentially avoiding off-target toxicities like bleeding and liver signals associated with traditional BTK tyrosine kinase inhibitors (TKIs).
- Other names
- BTK SH2 inhibitorBruton's tyrosine kinase SH2 domain inhibitor
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on BTK SH2 domain inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BTK SH2 domain inhibitor.